Ashajyothi M Siddappa, Erin Morris, Michael D Evans, Sarah Pelinka, Constance Adkisson
{"title":"需要药物治疗的新生儿阿片类药物戒断综合征婴儿的住院成长。","authors":"Ashajyothi M Siddappa, Erin Morris, Michael D Evans, Sarah Pelinka, Constance Adkisson","doi":"10.1155/2024/2212688","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> To assess inpatient growth parameter trajectories and to identify the type of opioid exposure and treatment characteristics influencing growth parameters of infants admitted to the newborn intensive care unit (NICU) for pharmacological treatment of neonatal opioid withdrawal syndrome (NOWS). <b>Methods:</b> Charts of term infants with NOWS admitted to NICU from 2012 to 2019, who received pharmacologic treatment, were reviewed. Intake (volume: mL/kg/day; calorie: kcal/kg/day) and growth parameter trajectories (weight, head circumference, and length) were analyzed based on the type of prenatal opioid exposure (short-acting opioids (SAOs), long-acting opioids (LAOs), and polysubstance), pharmacologic treatment, and sex. Growth measurement patterns over time were compared between groups using longitudinal mixed-effects models. <b>Results:</b> One hundred nineteen infants were included in the study with median birth weight <i>Z</i>-score of -0.19 at birth and decreased to a median of -0.72 at discharge. Exposure to SAO was associated with an increase in <i>Z</i>-scores nearing discharge across all growth parameters (<i>Z</i>-score for weight <i>p</i> = 0.03). Polysubstance exposure was associated with a decrease in <i>Z</i>-scores for length and head circumference throughout hospitalization. Infants with adjunct clonidine treatment had an increase in <i>Z</i>-score for weight trends. Male infants had a decrease in <i>Z</i>-scores for weight (male -0.96, female -0.59, interaction <i>p</i> = 0.06) and length (male -1.17, female -0.57, interaction <i>p</i> = 0.003) at Day 28. Despite the difference in growth trajectories, intake in terms of amount (mL/kg/day) and calorie intake (kcal/kg/day) was similar based on prenatal exposure, treatment, and sex. <b>Conclusion</b>: Infants with NOWS requiring pharmacologic treatment have a decrease in <i>Z</i>-scores for weight, length, and head circumference at birth and at hospital discharge. Infants with prenatal polysubstance exposure were at particular risk for poorer inpatient growth relative to infants exposed to SAO and LAO, indicated by lower <i>Z</i>-scores for length and occipital frontal circumference (OFC).</p>","PeriodicalId":51591,"journal":{"name":"International Journal of Pediatrics","volume":"2024 ","pages":"2212688"},"PeriodicalIF":1.3000,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11366048/pdf/","citationCount":"0","resultStr":"{\"title\":\"Inpatient Growth in Infants Requiring Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome.\",\"authors\":\"Ashajyothi M Siddappa, Erin Morris, Michael D Evans, Sarah Pelinka, Constance Adkisson\",\"doi\":\"10.1155/2024/2212688\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> To assess inpatient growth parameter trajectories and to identify the type of opioid exposure and treatment characteristics influencing growth parameters of infants admitted to the newborn intensive care unit (NICU) for pharmacological treatment of neonatal opioid withdrawal syndrome (NOWS). <b>Methods:</b> Charts of term infants with NOWS admitted to NICU from 2012 to 2019, who received pharmacologic treatment, were reviewed. Intake (volume: mL/kg/day; calorie: kcal/kg/day) and growth parameter trajectories (weight, head circumference, and length) were analyzed based on the type of prenatal opioid exposure (short-acting opioids (SAOs), long-acting opioids (LAOs), and polysubstance), pharmacologic treatment, and sex. Growth measurement patterns over time were compared between groups using longitudinal mixed-effects models. <b>Results:</b> One hundred nineteen infants were included in the study with median birth weight <i>Z</i>-score of -0.19 at birth and decreased to a median of -0.72 at discharge. Exposure to SAO was associated with an increase in <i>Z</i>-scores nearing discharge across all growth parameters (<i>Z</i>-score for weight <i>p</i> = 0.03). Polysubstance exposure was associated with a decrease in <i>Z</i>-scores for length and head circumference throughout hospitalization. Infants with adjunct clonidine treatment had an increase in <i>Z</i>-score for weight trends. Male infants had a decrease in <i>Z</i>-scores for weight (male -0.96, female -0.59, interaction <i>p</i> = 0.06) and length (male -1.17, female -0.57, interaction <i>p</i> = 0.003) at Day 28. Despite the difference in growth trajectories, intake in terms of amount (mL/kg/day) and calorie intake (kcal/kg/day) was similar based on prenatal exposure, treatment, and sex. <b>Conclusion</b>: Infants with NOWS requiring pharmacologic treatment have a decrease in <i>Z</i>-scores for weight, length, and head circumference at birth and at hospital discharge. Infants with prenatal polysubstance exposure were at particular risk for poorer inpatient growth relative to infants exposed to SAO and LAO, indicated by lower <i>Z</i>-scores for length and occipital frontal circumference (OFC).</p>\",\"PeriodicalId\":51591,\"journal\":{\"name\":\"International Journal of Pediatrics\",\"volume\":\"2024 \",\"pages\":\"2212688\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-08-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11366048/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Pediatrics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2024/2212688\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2024/2212688","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
摘要
目的:评估住院患者的生长参数轨迹,并确定阿片类药物暴露的类型以及影响新生儿重症监护室(NICU)中接受新生儿阿片类药物戒断综合征(NOWS)药物治疗的婴儿生长参数的治疗特征。研究方法回顾2012年至2019年期间新生儿重症监护室收治的接受药物治疗的NOWS足月婴儿的病历。根据产前阿片类药物暴露类型(短效阿片类药物(SAOs)、长效阿片类药物(LAOs)和多效阿片类药物)、药物治疗和性别,分析了摄入量(体积:毫升/千克/天;热量:千卡/千克/天)和生长参数轨迹(体重、头围和身长)。采用纵向混合效应模型比较了各组间不同时期的生长测量模式。研究结果研究共纳入了 119 名婴儿,他们出生时的出生体重 Z 值中位数为-0.19,出院时降至-0.72。暴露于 SAO 与接近出院时所有生长参数的 Z 值增加有关(体重 Z 值 p = 0.03)。在整个住院期间,接触多种物质与身长和头围的 Z 值下降有关。接受氯尼丁辅助治疗的婴儿体重Z值呈上升趋势。男婴在第 28 天时体重 Z 值下降(男婴-0.96,女婴-0.59,交互作用 p = 0.06),身长 Z 值下降(男婴-1.17,女婴-0.57,交互作用 p = 0.003)。尽管生长轨迹不同,但根据产前暴露、治疗和性别,摄入量(毫升/千克/天)和卡路里摄入量(千卡/千克/天)相似。结论患有需要药物治疗的 NOWS 的婴儿在出生时和出院时体重、身长和头围的 Z 值均有所下降。与暴露于SAO和LAO的婴儿相比,产前暴露于多种物质的婴儿在住院期间生长发育较差的风险尤其大,这表现在身长和枕额周(OFC)的Z值较低。
Inpatient Growth in Infants Requiring Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome.
Aim: To assess inpatient growth parameter trajectories and to identify the type of opioid exposure and treatment characteristics influencing growth parameters of infants admitted to the newborn intensive care unit (NICU) for pharmacological treatment of neonatal opioid withdrawal syndrome (NOWS). Methods: Charts of term infants with NOWS admitted to NICU from 2012 to 2019, who received pharmacologic treatment, were reviewed. Intake (volume: mL/kg/day; calorie: kcal/kg/day) and growth parameter trajectories (weight, head circumference, and length) were analyzed based on the type of prenatal opioid exposure (short-acting opioids (SAOs), long-acting opioids (LAOs), and polysubstance), pharmacologic treatment, and sex. Growth measurement patterns over time were compared between groups using longitudinal mixed-effects models. Results: One hundred nineteen infants were included in the study with median birth weight Z-score of -0.19 at birth and decreased to a median of -0.72 at discharge. Exposure to SAO was associated with an increase in Z-scores nearing discharge across all growth parameters (Z-score for weight p = 0.03). Polysubstance exposure was associated with a decrease in Z-scores for length and head circumference throughout hospitalization. Infants with adjunct clonidine treatment had an increase in Z-score for weight trends. Male infants had a decrease in Z-scores for weight (male -0.96, female -0.59, interaction p = 0.06) and length (male -1.17, female -0.57, interaction p = 0.003) at Day 28. Despite the difference in growth trajectories, intake in terms of amount (mL/kg/day) and calorie intake (kcal/kg/day) was similar based on prenatal exposure, treatment, and sex. Conclusion: Infants with NOWS requiring pharmacologic treatment have a decrease in Z-scores for weight, length, and head circumference at birth and at hospital discharge. Infants with prenatal polysubstance exposure were at particular risk for poorer inpatient growth relative to infants exposed to SAO and LAO, indicated by lower Z-scores for length and occipital frontal circumference (OFC).
期刊介绍:
International Journal of Pediatrics is a peer-reviewed, open access journal that publishes original researcharticles, review articles, and clinical studies in all areas of pediatric research. The journal accepts submissions presented as an original article, short communication, case report, review article, systematic review, or letter to the editor.